Bildkälla: Stockfoto

Medivir: Deal for Remetinostat Getting Close? - Redeye

Redeye is positively surprised by the news of renegotiated terms for remetinostat, which we believe significantly increases the likelihood of a licensing deal. Pending the outcome of business development activities for the project, we will reconsider our base case for a potential upgrade.

Redeye is positively surprised by the news of renegotiated terms for remetinostat, which we believe significantly increases the likelihood of a licensing deal. Pending the outcome of business development activities for the project, we will reconsider our base case for a potential upgrade.
Börsvärldens nyhetsbrev
ANNONSER